April 9, 2019 Biodesix, Boulder, Colo, has recently presented new data demonstrating that the company’s VeriStrat test is predictive of outcomes for patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors in the frontline setting, even when adjusted for PD-L1 status.1,2
The VeriStrat test is a multivariate, mass-spectrometry based test that measures circulating proteins in the ... Read more
December 12, 2018
Biodesix’s primary immunotherapy resistance test demonstrated utility in classifying NSCLC patients treated with nivolumab by overall survival. The test classification is independent of PD-L1 status.
“Anti-PD-1 therapy is capable of restoring immunity and has greatly increased overall survival rates for patients. However, we know that this therapy does not benefit ... Read more
November 13, 2018
“Biodesix announced in the third quarter of 2018 that in a study of samples from non-small cell lung cancer patients, the company’s VeriStrat test was found to be a significant predictor of outcomes (independent of ECOG Performance Status categories), patient EGFR mutation status, treatment received and other clinical variables.”
Read the full story.
October 24, 2018
“Yearly CT scans of high-risk lung cancer patients has increased the early diagnosis of lung cancer as well as the identification of pulmonary nodules. Yet not all lung nodules are cancerous. The BDX-XL2 test has shown early promise in ruling out cancer through blood samples, including a finding by ... Read more
August 31, 2018
“The Biodesix VeriStrat test received an extra dose of validation last week through a 1,048-patient study published in the Oncologist. The study demonstrated the prognostic value of the VeriStrat test in patients with non-small cell lung cancer (NSCLC).”
Read the full story.
August 22, 2018
“…the growing use of ddPCR assays for identifying the subset of patients who should be placed on targeted therapy options is providing carefully measured results with rapid turnaround time for optimal clinical utility. This approach enabled by liquid biopsy means that physicians do not have to wait weeks for ... Read more
August 3, 2018
“Methods for measuring ctDNA, circulating tumour RNA (ctRNA), and circulating proteomic signatures from the blood are non-invasive and provide diagnostic and independent prognostic information that can help drive therapeutic strategy, as well as facilitate patient-physician conversations about prognosis and care preferences.” Read the full story.